US equities |
SPCX $166.88 ▲+4.98% NVDA $236.47 ▲+1.08% MU $1,063.98 ▼-1.01% TSLA $377.76 ▲+1.94% MSFT $526.48 ▲+1.73% SNDK $1,714.14 ▼-0.34% INTC $116.77 ▼-2.15% META $745.33 ▲+2.37%
FinancialContent

Globus Medical, Inc. Class A Common Stock (NY:GMED)

75.82 +0.22 (+0.29%)
Delayed Quote Updated: 11:28 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Globus Medical, Inc. Class A Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Centuri, Medpace, Customers Bancorp, and Globus and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
A Glimpse Into The Expert Outlook On Globus Medical Through 8 Analysts ↗
 
Via Benzinga
News headline image
Globus Medical, Inc. (GMED) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Looking Into Globus Medical's Recent Short Interest ↗
 
Via Benzinga
News headline image
What 8 Analyst Ratings Have To Say About Globus Medical ↗
 
Via Benzinga
News headline image
NYSE:GMED is showing decent growth, but is still valued reasonably. ↗
NYSE:GMED, a growth stock which is not overvalued. 
Via Chartmill
News headline image
GMED Investors Have Opportunity to Join Globus Medical, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Globus Medical Launches ADIRA™ XLIF™ Plate System
From Globus Medical
Via GlobeNewswire
News headline image
Investors should take note of NYSE:GMED, a growth stock that remains attractively priced. ↗
GLOBUS MEDICAL INC - A (NYSE:GMED) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
News headline image
GLOBUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Globus Medical, Inc. on Behalf of Globus Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Peering Into Globus Medical's Recent Short Interest ↗
 
Via Benzinga
News headline image
Where Globus Medical Stands With Analysts ↗
 
Via Benzinga
News headline image
Globus Medical, Inc. (GMED) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Globus Medical, Inc. (GMED)
From Kirby McInerney LLP
Via Business Wire
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Globus Medical, Inc. (GMED) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
NYSE:GMED is not too expensive for the growth it is showing. ↗
Looking for growth without the hefty price tag? Consider NYSE:GMED. 
Via Chartmill
News headline image
Deep Dive Into Globus Medical Stock: Analyst Perspectives (7 Ratings) ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Globus Medical, Inc. (GMED) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of Globus Medical, Inc. (GMED) on Behalf of Investors
From Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Globus Medical (GMED) Q2 2024 Earnings Call Transcript ↗
GMED earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
GMED Stock Earnings: Globus Medical Beats EPS, Beats Revenue for Q2 2024 ↗
GMED stock results show that Globus Medical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Globus Medical Reports Second Quarter 2024 Results
From Globus Medical
Via GlobeNewswire
News headline image
Globus Medical Receives FDA 510(k) Clearance for ExcelsiusFlex™ and ACTIFY™ 3D Total Knee System
From Globus Medical
Via GlobeNewswire
News headline image
Globus Medical Schedules Second Quarter Earnings Release and Conference Call
From Globus Medical
Via GlobeNewswire
News headline image
For those who appreciate growth without the sticker shock, NYSE:GMED is worth considering. ↗
GLOBUS MEDICAL INC - A (NYSE:GMED) is showing decent growth, but is still valued reasonably. 
Via Chartmill
News headline image
Staar Surgical Stock Earns RS Rating Upgrade ↗
On Thursday, lens maker Staar Surgical stock had its Relative Strength (RS) Rating upgraded to 87 from 77. 
Via Investor's Business Daily
News headline image
Soft Inflation Data Boosts Small Caps, Real Estate, Regional Banks; Traders Anticipate Fed Rate Cuts As Stocks React ↗
U.S. inflation slowed in May, boosting rate cut prospects. Markets rally ahead of FOMC meeting and assign 70% chance of rate cut in September. 
Via Benzinga
Topics Economy
News headline image
Stryker Stock Sees RS Rating Treks Higher To 71 ↗
Stryker stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 63 to 71. 
Via Investor's Business Daily
News headline image
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Don't overlook NYSE:GMED—a stock with solid growth prospects and a reasonable valuation. ↗
Looking for growth without the hefty price tag? Consider GLOBUS MEDICAL INC - A (NYSE:GMED). 
Via Chartmill
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >